Abbott's Q1 Results Meet Expectations but Guidance Cut Damps Sentiment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 hours ago
0mins
Should l Buy ABT?
Source: Fool
- Sales Performance: Abbott's Q1 sales totaled nearly $11.2 billion, reflecting an almost 8% year-over-year increase; however, despite meeting analyst expectations, the stock fell by 6% as investors reacted negatively to the results.
- Net Income Stability: The company's net income under GAAP rose modestly by 5% to just over $2 million, or $1.15 per share, indicating stable profitability, yet this was insufficient to bolster investor confidence in the stock.
- Guidance Downgrade: Abbott lowered its full-year 2026 adjusted EPS guidance to $5.38 to $5.58, down from the previous forecast of $5.55 to $5.80, reflecting a cautious outlook on profitability, particularly due to anticipated share dilution from the Exact Sciences acquisition.
- Medical Devices Growth: Abbott's medical devices segment saw a 13% year-over-year sales increase, with double-digit growth in electrophysiology, rhythm management, diabetes care, and heart failure products, showcasing strong performance in this area despite the overall market's negative sentiment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABT
Wall Street analysts forecast ABT stock price to rise
19 Analyst Rating
17 Buy
2 Hold
0 Sell
Strong Buy
Current: 101.560
Low
136.00
Averages
148.11
High
169.00
Current: 101.560
Low
136.00
Averages
148.11
High
169.00
About ABT
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Abbott Laboratories Reports Mixed Q1 2026 Earnings Amid Lowered EPS Outlook
- Revenue Growth: Abbott Laboratories reported an approximately 8% year-over-year revenue increase in Q1 2026, reaching $11.2 billion, surpassing consensus estimates by $160 million, primarily driven by a notable 13% growth in its MedTech division, marking the company's first top-line beat in two quarters.
- Lowered EPS Outlook: Despite the revenue beat, Abbott has revised its 2026 adjusted diluted EPS outlook down to $5.38–$5.58 from the previous range of $5.55–$5.80, largely due to a $21 billion acquisition of Exact Sciences that introduced $0.20 per share dilution, resulting in a decline in share price during trading.
- Declining Market Rating: Abbott ranks last among the top 10 large-cap U.S. healthcare equipment stocks according to Seeking Alpha's Quant Rating, with a score of just 2.86, reflecting headwinds from diluted guidance, an underperforming Nutrition segment, and compressed gross margins.
- Future Sales Growth Forecast: The company forecasts a comparable sales growth of 6.5%-7.5% for 2026, while integrating Exact Sciences with a projected $0.20 EPS dilution, indicating that Abbott aims to maintain growth expectations despite facing significant challenges.
See More
Abbott's Shares Decline 2% in Premarket Trading Following Q1 Results
- Market Reaction: Shares of the company fell by 2% in pre-market trading following the release of Q1 results.
- Earnings Report: The Q1 results have influenced investor sentiment, leading to a decline in stock prices.
See More
Abbott's Q1 Results Meet Expectations but Guidance Cut Damps Sentiment
- Sales Performance: Abbott's Q1 sales totaled nearly $11.2 billion, reflecting an almost 8% year-over-year increase; however, despite meeting analyst expectations, the stock fell by 6% as investors reacted negatively to the results.
- Net Income Stability: The company's net income under GAAP rose modestly by 5% to just over $2 million, or $1.15 per share, indicating stable profitability, yet this was insufficient to bolster investor confidence in the stock.
- Guidance Downgrade: Abbott lowered its full-year 2026 adjusted EPS guidance to $5.38 to $5.58, down from the previous forecast of $5.55 to $5.80, reflecting a cautious outlook on profitability, particularly due to anticipated share dilution from the Exact Sciences acquisition.
- Medical Devices Growth: Abbott's medical devices segment saw a 13% year-over-year sales increase, with double-digit growth in electrophysiology, rhythm management, diabetes care, and heart failure products, showcasing strong performance in this area despite the overall market's negative sentiment.
See More
Abbott Lowers Full-Year Profit Guidance, Stock Drops
- Performance Overview: Abbott's Q1 sales reached nearly $11.2 billion, an 8% year-over-year increase, but net income only grew modestly by 5% to just over $2 million, indicating pressure on profitability.
- Guidance Cut: The company lowered its 2026 adjusted EPS forecast to $5.38 to $5.58, down from $5.55 to $5.80, reflecting a cautious outlook on future profitability amid market uncertainties.
- Market Reaction: Following the significant guidance cut, Abbott's stock fell by 6% after the earnings release, as investor concerns about future prospects intensified, leading to a negative market sentiment.
- Medical Devices Performance: Despite the overall disappointing results, Abbott's medical devices segment saw a 13% sales increase, indicating strong demand in this area, which may support the company's future growth.
See More
US Stocks Close Higher with Chipmakers Rallying
- Market Recovery: On Thursday, the S&P 500 rose by 0.26% and the Nasdaq 100 by 0.49%, reaching new highs, indicating a strong rebound after early losses and reflecting investor confidence in economic recovery.
- Chip Sector Boost: Taiwan Semiconductor Manufacturing Co raised its 2026 revenue forecast, highlighting strong AI demand, which propelled chipmakers' stock prices, particularly benefiting major suppliers to Nvidia and Apple, further enhancing market optimism.
- Oil Price Impact: Despite the stock market gains, crude oil prices surged over 3%, raising concerns about the Middle East situation and limiting the market's upward momentum, illustrating the potential impact of energy prices on the overall economy.
- Mixed Economic Data: Initial jobless claims fell to 207,000, exceeding expectations and indicating labor market strength, but unexpected declines in manufacturing production reflect economic uncertainty, which could influence future monetary policy.
See More
US Stocks Dip Slightly as Chipmakers Weigh on Market
- Market Performance: The S&P 500 index fell by 0.15%, the Dow Jones Industrial Average decreased by 0.06%, and the Nasdaq 100 dropped by 0.21%, indicating a slight market pullback after reaching new highs, particularly pressured by weakness in chipmakers.
- Economic Data: Initial jobless claims in the US fell by 11,000 to 207,000, indicating a stronger labor market than the expected 213,000; additionally, the Philadelphia Fed business outlook unexpectedly rose by 8.6 to a 15-month high of 26.7, reflecting potential economic recovery.
- Oil Price Fluctuations: WTI crude oil prices increased by over 1% as the US naval blockade of the Strait of Hormuz enters its fourth day, which could exacerbate global oil and fuel shortages, impacting future energy market stability.
- Earnings Season: Q1 earnings for the S&P 500 are projected to rise by 12% year-over-year, but excluding the technology sector, the earnings growth is only 3%, the lowest in two years, indicating a cautious market outlook on profit growth.
See More
Abbott Laboratories Reports Mixed Q1 2026 Earnings Amid Lowered EPS Outlook
- Revenue Growth: Abbott Laboratories reported an approximately 8% year-over-year revenue increase in Q1 2026, reaching $11.2 billion, surpassing consensus estimates by $160 million, primarily driven by a notable 13% growth in its MedTech division, marking the company's first top-line beat in two quarters.
- Lowered EPS Outlook: Despite the revenue beat, Abbott has revised its 2026 adjusted diluted EPS outlook down to $5.38–$5.58 from the previous range of $5.55–$5.80, largely due to a $21 billion acquisition of Exact Sciences that introduced $0.20 per share dilution, resulting in a decline in share price during trading.
- Declining Market Rating: Abbott ranks last among the top 10 large-cap U.S. healthcare equipment stocks according to Seeking Alpha's Quant Rating, with a score of just 2.86, reflecting headwinds from diluted guidance, an underperforming Nutrition segment, and compressed gross margins.
- Future Sales Growth Forecast: The company forecasts a comparable sales growth of 6.5%-7.5% for 2026, while integrating Exact Sciences with a projected $0.20 EPS dilution, indicating that Abbott aims to maintain growth expectations despite facing significant challenges.
See More
Abbott's Shares Decline 2% in Premarket Trading Following Q1 Results
- Market Reaction: Shares of the company fell by 2% in pre-market trading following the release of Q1 results.
- Earnings Report: The Q1 results have influenced investor sentiment, leading to a decline in stock prices.
See More
Abbott's Q1 Results Meet Expectations but Guidance Cut Damps Sentiment
- Sales Performance: Abbott's Q1 sales totaled nearly $11.2 billion, reflecting an almost 8% year-over-year increase; however, despite meeting analyst expectations, the stock fell by 6% as investors reacted negatively to the results.
- Net Income Stability: The company's net income under GAAP rose modestly by 5% to just over $2 million, or $1.15 per share, indicating stable profitability, yet this was insufficient to bolster investor confidence in the stock.
- Guidance Downgrade: Abbott lowered its full-year 2026 adjusted EPS guidance to $5.38 to $5.58, down from the previous forecast of $5.55 to $5.80, reflecting a cautious outlook on profitability, particularly due to anticipated share dilution from the Exact Sciences acquisition.
- Medical Devices Growth: Abbott's medical devices segment saw a 13% year-over-year sales increase, with double-digit growth in electrophysiology, rhythm management, diabetes care, and heart failure products, showcasing strong performance in this area despite the overall market's negative sentiment.
See More
Abbott Lowers Full-Year Profit Guidance, Stock Drops
- Performance Overview: Abbott's Q1 sales reached nearly $11.2 billion, an 8% year-over-year increase, but net income only grew modestly by 5% to just over $2 million, indicating pressure on profitability.
- Guidance Cut: The company lowered its 2026 adjusted EPS forecast to $5.38 to $5.58, down from $5.55 to $5.80, reflecting a cautious outlook on future profitability amid market uncertainties.
- Market Reaction: Following the significant guidance cut, Abbott's stock fell by 6% after the earnings release, as investor concerns about future prospects intensified, leading to a negative market sentiment.
- Medical Devices Performance: Despite the overall disappointing results, Abbott's medical devices segment saw a 13% sales increase, indicating strong demand in this area, which may support the company's future growth.
See More
US Stocks Close Higher with Chipmakers Rallying
- Market Recovery: On Thursday, the S&P 500 rose by 0.26% and the Nasdaq 100 by 0.49%, reaching new highs, indicating a strong rebound after early losses and reflecting investor confidence in economic recovery.
- Chip Sector Boost: Taiwan Semiconductor Manufacturing Co raised its 2026 revenue forecast, highlighting strong AI demand, which propelled chipmakers' stock prices, particularly benefiting major suppliers to Nvidia and Apple, further enhancing market optimism.
- Oil Price Impact: Despite the stock market gains, crude oil prices surged over 3%, raising concerns about the Middle East situation and limiting the market's upward momentum, illustrating the potential impact of energy prices on the overall economy.
- Mixed Economic Data: Initial jobless claims fell to 207,000, exceeding expectations and indicating labor market strength, but unexpected declines in manufacturing production reflect economic uncertainty, which could influence future monetary policy.
See More
US Stocks Dip Slightly as Chipmakers Weigh on Market
- Market Performance: The S&P 500 index fell by 0.15%, the Dow Jones Industrial Average decreased by 0.06%, and the Nasdaq 100 dropped by 0.21%, indicating a slight market pullback after reaching new highs, particularly pressured by weakness in chipmakers.
- Economic Data: Initial jobless claims in the US fell by 11,000 to 207,000, indicating a stronger labor market than the expected 213,000; additionally, the Philadelphia Fed business outlook unexpectedly rose by 8.6 to a 15-month high of 26.7, reflecting potential economic recovery.
- Oil Price Fluctuations: WTI crude oil prices increased by over 1% as the US naval blockade of the Strait of Hormuz enters its fourth day, which could exacerbate global oil and fuel shortages, impacting future energy market stability.
- Earnings Season: Q1 earnings for the S&P 500 are projected to rise by 12% year-over-year, but excluding the technology sector, the earnings growth is only 3%, the lowest in two years, indicating a cautious market outlook on profit growth.
See More
